Creo Medical (GB:CREO) has released an update.
Creo Medical Group plc has announced the sale of a 51% stake in its European subsidiary to Micro-Tech (Nanjing) Co. Ltd for €36.7m, which will enhance Creo’s balance sheet and enable continued investment in its core business. This strategic partnership is set to expand Creo’s endoscopic therapy product range and strengthen its commercial platform, with expectations for the deal to complete in Q1 2025. Creo Europe’s managing director will remain, ensuring continuity in the business’s operation alongside the new partnership.
For further insights into GB:CREO stock, check out TipRanks’ Stock Analysis page.
